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Background: The most common microcytic and hypochromic anemias are iron deﬁciency
anemia and thalassemia trait. Several indices to discriminate iron deﬁciency anemia from
thalassemia trait have been proposed as simple diagnostic tools. However, some of the best
discriminative indices use parameters in the formulas that are only measured in modern
counters and are not always available in small laboratories.
The development of an index with good diagnostic accuracy based only on parameters
derived from the blood cell count obtained using simple counters would be useful in the
clinical routine. Thus, the aim of this study was to develop and validate a discriminative
index to differentiate iron deﬁciency anemia from thalassemia trait.
Methods: To develop and to validate the new formula, blood count data from 106 (thalassemia
trait: 23 and iron deﬁciency: 83) and 185 patients (thalassemia trait: 30 and iron deﬁciency:
155)  were used, respectively. Iron deﬁciency, -thalassemia trait and -thalassemia trait were
conﬁrmed by gold standard tests (low serum ferritin for iron deﬁciency anemia, HbA2 > 3.5%
for  -thalassemia trait and using molecular biology for the -thalassemia trait).
Results: The sensitivity, speciﬁcity, efﬁciency, Youden’s Index, area under receiver operating
characteristic curve and Kappa coefﬁcient of the new formula, called the Matos & Carvalho
Index were 99.3%, 76.7%, 95.7%, 76.0, 0.95 and 0.83, respectively.
Conclusion: The performance of this index was excellent with the advantage of being solely
dependent on the mean corpuscular hemoglobin concentration and red blood cell count
obtained from simple automatic counters and thus may be of great value in underdeveloped
and developing countries.©  2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Publishedby  Elsevier Editora Lt
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nemia affects about 800 million children and women world-
ide. The most common causes of anemia are iron deﬁciency
nemia (IDA) and thalassemia trait (TT).1–3 According to World
ealth Organization (WHO) estimates in 2004, IDA resulted in
73,000 deaths and the loss of 19.7 million disability-adjusted
ife years, accounting for 1.3% of the global total, with 97%
ccurring in low-  and middle-income countries.3,4
Differential diagnosis of microcytic anemias is of great clin-
cal importance since prognosis and treatment are distinct.
he ﬁrst step to diagnose microcytic anemias is by the micro-
copic analysis of blood ﬁlm and determination of red blood
ell (RBC) indices using cell counters. Considering the great
imilarity between IDA and TT, complementary lab methods
re needed besides the routine blood exam. Currently, diag-
osis of IDA is obtained by evaluating the iron metabolism,
ncluding serum iron, total serum iron binding capacity and
erum ferritin measurements. Diagnosis of the -thalassemia
rait (-TT) is usually made by hemoglobin electrophoresis and
bA2 levels (>3.5%).5,6 On the other hand, diagnosis of the
-thalassemia trait (-TT) is conﬁrmed by investigating muta-
ions in the  gene. Despite their great utility, gold standard
ests for the diagnosis of these microcytic and hypochromic
nemias involve time-consuming methodologies, high costs
nd are inaccessible to poorer populations.5–8
In an attempt to simplify the differential diagnosis between
DA and TT, several indices using blood cell count param-
ters have been suggested.9–16 The formula developed by
reen & King {[(MCV2) × RDW]/(Hb × 100) where MCV  is mean
orpuscular volume, RDW is RBC distribution width and
b is hemoglobin} has, according to many  studies, a good
erformance.16–18 However, this formula is dependent on the
DW, a parameter that is not provided by all automatic coun-
ers. Furthermore, the currently existing indexes reported in
he literature have not been developed using molecular biol-
gy to diagnose -thalassemia, which is necessary to exclude
oncomitant diseases.
The aim of this study was to develop and validate a new
ndex that discriminates between IDA and TT employing very
imple parameters that are provided by all automatic blood
ounters. This study used molecular techniques to diagnose
T and exclude the presence of this disorder in IDA patients.
ethods
opulation  evaluated  to  develop  the  new  index
wo groups of patients were selected to develop this index,
amely over 18-year-old individuals with IDA or TT. For inclu-
ion in the IDA group, patients had hemoglobin levels below
2 g/dL for women and 13 g/dL for men,19 MCV and mean cor-
uscular hemoglobin (MCH) below 80 fL and 27 pg for both
enders, respectively,20 and ferritin < 6 ng/mL for women and
8 ng/mL for men, thereby characterizing IDA. Exclusion crite-
ia for the IDA group were the presence of malignancies and
nﬂammatory/infectious diseases or presence of mutations
ssociated with -TT (3.7, 4.2, 20.5, MED,  SEA, THAI, FIL and 1 6;3  8(3):214–219 215
Hph). Patients with these mutations were excluded so that this
group did not have individuals presenting the two  diseases
simultaneously.
For inclusion in the TT group, patients had the MCV
below 80 fL. -TT carriers were conﬁrmed by hemoglobin
electrophoresis at pH 8.6 and HbA2 levels > 3.5%.5 -TT was
conﬁrmed by the presence of mutations. All patients with
malignancies or inﬂammatory/infectious diseases based on
clinical data and personal information obtained from medi-
cal records were excluded from this group, as were patients
suffering from iron deﬁciency identiﬁed by measuring ferritin
serum levels.
Sample  collection,  hematological  and  biochemical
evaluations
Peripheral blood (5 mL)  was collected in tubes containing
ethylenediaminetetraacetic acid (EDTA) at a ﬁnal concentra-
tion of 1 mg/mL. Blood cell count results were obtained using
automatic cell counters (ABX Pentra DX-120, HoribaMedical
DF® in IPSEMG and Sysmex® XE-2100 in Hospital Univer-
sitário). Hemoglobin electrophoresis was performed at pH 8.6
using a semi-automated system (Hydrasys® of Sebia®) and
HbA2 was measured by the elution method using a cellulose
acetate strip.5 In addition, these samples were used to investi-
gate eight mutations that cause -TT (3.7, 4.2, 20.5, MED,  SEA,
THAI, FIL and Hph). Another sample of the peripheral blood
(5 mL)  was collected without anticoagulant to evaluate ferritin
values. Serum ferritin levels were determined by Immulite®
DPC® using the chemiluminescent immunoassay technique
and Immulite 2000 DPC® kits (Diagnostic Products Corpora-
tion, Los Angeles, CA, USA) with reference values between
28 and 397 ng/mL for men  and between 6 and 159 ng/mL for
women.
Molecular  analysis
Genomic DNA was extracted from peripheral blood leuko-
cytes using the Gentra Puregene Blood Kit (Qiagen®, Germany)
according to the manufacturer’s instructions. Investigation of
the deletional mutations (3.7, 4.2, MED,  20.5, SEA, FIL and
THAI) was performed by multiplex polymerase chain reaction
(PCR) according to the methodology described by Tan et al.21
Oligonucleotides were synthesized by Promega® (Promega®,
USA), whose sequences were also described by Tan et al.21 A
control, the LIS1 gene located on chromosome 17, was used in
the reaction to detect these mutations in order to verify the
success of ampliﬁcation. After ampliﬁcation, the PCR product
was subjected to electrophoresis on 1.5% agarose gel.
Development  of  the  new  index
A mathematical formula to discriminate between IDA and
TT was developed with the support of a statistician of the
Universidade Federal de Minas Gerais, Brazil, using values
of the hematological parameters of 23 patients with -TT
and 83 patients with IDA conﬁrmed using gold standard tests
(HbA2 > 3.5% in -TT and low serum ferritin in IDA).5
Both Fisher discriminant (linear and nonlinear) and
receiver operating characteristic (ROC) curve analyses were
oter.216  rev bras hematol hem
employed to create this new index. Based on the largest area
under the curve, the formula with the best performance was
the one that took into account the RBC count and mean cor-
puscular hemoglobin concentration (MCHC) parameters.
The adjusted formula of the new index developed in
this study is Matos & Carvalho Index (MCI) = (1.91 × RBC) +
(0.44 × MCHC).
According to the ROC curve, the MCI  presented a cut-off
point with a value of 23.85 to discriminate between IDA and TT.
If the index is <23.85, the patient is classiﬁed as an IDA patient,
while values >23.85 classify the individual as a TT carrier.
Validation  of  the  Matos  &  Carvalho  Index
In order to validate the MCI, a cross-sectional study was
conducted from 2009 to 2011 in two hospitals (Hospital Gov-
ernador Israel Pinheiro – IPSEMG and Hospital Universitário)
in Belo Horizonte, Minas Gerais, Brazil. A total of 227 outpa-
tients were included in this study. Classiﬁcation of patients as
having IDA or TT was carried out according to the aforemen-
tioned criteria. From 227 patients, 197 patients presented IDA
and 30 patients were TT carriers. Of the 197 patients with IDA,
42 had mutations related to -thalassemia and were excluded
(Figure 1). Thus, the IDA group was composed of 155 patients.
In the TT group, 24 patients had -TT and the other six patients
had -TT (Figure 1).
Statistical  analysis
Statistical analysis was performed using the GraphPad Prism
5.0 software (Graph-Pad Software Inc., La Jolla, CA). Normality
of the CBC data was assessed using the Kolmogorov–Smirnoff
test. Considering the nonparametric nature of all data sets,
the Mann–Whitney test was used to investigate differences
between the two groups. Differences were considered signiﬁ-
cant when the p-value < 0.05.
IDA (n=197)
(Ferritin:   <6;   <28)
Investigated
mutations
Positive
(IDA and α-TT, n=42)
Negative
(IDA n=155)
Eligible (IDA) Not eligible
Samples (n=2
(Hb:   <12,   <13 g/dL; MCV<
Figure 1 – Design of study used for the validation of the Matos &
volume; MCH: mean corpuscular hemoglobin; IDA: iron deﬁcienc
negative 2 0 1 6;3  8(3):214–219
The sensitivity, speciﬁcity, efﬁciency and Youden’s Index
were calculated to investigate the performance of the MCI to
differentiate between IDA and TT. Besides the calculation of
these parameters, the ROC curve of discriminant formulas was
plotted and its area determined using GraphPad Prism 5.0. The
largest area under the curve indicates the index most likely to
correctly discriminate patients with one of these anemias.
The validity of the MCI was compared to the results from
molecular techniques (-TT), HbA2 measurement (-TT) and
ferritin measurement (IDA) as reference standards, respec-
tively. In order to investigate the degree of agreement between
the results, the Kappa coefﬁcient was calculated using the
software OpenEpi version 2.3.1. Interpretation of Kappa was
according to the following scale: excellent 1.00–0.81; good
0.80–0.61; moderate 0.61–0.40; weak 0.40–0.21; and absence of
agreement 0.20–0 when compared to the gold standards in the
diagnosis of IDA and TT.22
Ethical  statement
This study was approved by both the Ethics Committees of the
Universidade Federal de Minas Gerais (protocol n◦ 344/09) and
the Hospital Governador Israel Pinheiro (protocol n◦ 361/09) in
Belo Horizonte, Brazil. Patients were informed of the objectives
of the research and signed informed consent forms before
blood sampling and data collection.
Results
Hematological  parameters
The median and interquartile ranges of CBC parameters for
the 185 patients (TT and IDA groups) enrolled in the vali-
dation of MCI were calculated. RBC, Hb, hematocrit and MCHC
values for TT patients were signiﬁcantly higher than those
observed for IDA patients whereas MCV, MCH, RDW and the
Ferritin (ng/mL)
Eligible (TT)
Posit., HbA2<3.5 g/dL(α-TT; n=6)
Negat., HbA2>3.5 g/dLβ-TT (n=24)
Investigated
mutations and HbA2
27)
80 fL; MCH<27pg)
TT (n=30)
(Ferritin:   >6;   >28)
 Carvalho Index. Hb: hemoglobin; MCV:  mean corpuscular
y anemia; TT: thalassemia trait; Posit: positive; Negat:
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Table 1 – Hematological parameters of patients with iron deﬁciency anemia and thalassemia trait used to validate the
Matos & Carvalho Index.
Parameter Iron deﬁciency anemia (n = 155) Thalassemia trait (n = 30) p-value
RBC (106/L) 4.4 (4.2–4.7) 5.4 (5.1–5.7) <0.0001
Hb (g/dL) 10.0 (9.3–10.7) 10.9 (10.5–11.8) <0.0001
Ht (%) 32.2 (30.3–33.8) 34.6 (33.2–36.2) <0.0001
MCV (fL) 73.0 (67.0–76.0) 63.8 (61.6–68.5) <0.0001
MCH (pg) 22.7 (20.8–24.1) 20.4 (19.7–21.6) <0.0001
MCHC (%) 31.2 (30.4–31.8) 31.8 (31.2–32.6) 0.0003
RDW (%) 17.9  (16.6–19.4) 15.9 (15.3–16.9) <0.0001
PLT (103/L) 319.0 (257.0–390.0) 233.5 (197.5–275.3) <0.0001
RBC: red blood count; Hb: hemoglobin; Ht: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean
corpuscular hemoglobin concentration; RDW: red blood cell distribution width; PLT: platelet count.
The data are presented as medians and interquartile range.
Table 2 – Performance of Matos & Carvalho Index in the discrimination between iron deﬁciency anemia and thalassemia
trait.
Group IDA TT
Sensitivity % (95% CI) 99.3 (96.4–99.9) 76.7 (59.1–88.2)
Speciﬁcity % (95% CI) 76.7 (59.1–88.2) 99.3 (96.4–99.9)
Accuracy (%) 95.7 (91.7–97.8)
Youden’s Index 76.0
AUC (95% CI) 0.95 (0.90–1.00)
Kappa coefﬁcient (95% CI) 0.83  (0.68–0.97)
ence interval; AUC: area under receiver operating characteristic curve.
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Figure 2 – Receiver operating characteristic curve for the
Matos & Carvalho Index.IDA: iron deﬁciency anemia; TT: thalassemia trait; 95% CI: 95% conﬁd
latelet count were signiﬁcantly lower than those observed for
DA patients. Hematological data of the two study groups are
hown in Table 1.
alidation  of  the  index
CI  values were calculated for all patients using CBC data.
CI  correctly diagnosed 154 (99.3%) of the 155 patients with
DA and 23 (76.7%) of the 30 patients with TT. MCI performance
as analyzed by calculating sensitivity [99.3; 95% conﬁdence
nterval (95% CI): 96.4–99.9], speciﬁcity (76.7; 95% CI: 59.1–88.2),
ccuracy (95.7; 95% CI: 91.7–97.8), area under ROC curve (0.95;
5% CI: 0.90–1.00), Youden’s Index (76.0) and the kappa coefﬁ-
ient (0.83; 95% CI: 0.68–0.97) (Table 2). Figure 2 shows the ROC
urve for the MCI. This index showed high accuracy and has
evealed excellent agreement with the gold standard diagnos-
ic techniques as well as good clinical applicability as a method
f screening.
iscussion
n this study, a new index (MCI) was developed using detailed
tatistical analysis with the aim of accurately discriminat-
ng between IDA and TT. This formula produced excellent
iagnostic accuracy and the parameters, such as sensitivity,
fﬁciency, Youden’s Index, and area under the ROC curve were
uite high. MCI  showed excellent agreement with the gold
tandard methods of diagnosis for these anemias, showing
ood applicability as a screening tool in the clinical practice.Furthermore, the MCI  was developed using a molecular biol-
ogy technique to diagnose -thalassemia, which is necessary
to exclude concomitant diseases. The indexes currently
described in the literature were not developed using this
technique.
An important result obtained for MCI is the high sensitivity
to detect IDA (99.3%). As sensitivity is a parameter that indi-
cates the proportion of individuals correctly identiﬁed with
the disease, the high sensitivity of the MCI  in the detection
of IDA indicates that it is a good tool to identify this disor-
der. One may argue that a discriminative index that correctly
diagnoses IDA would clinically be more  valuable compared to
oter.
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those that correctly diagnose TT. This is because one month
of iron supplementation to a patient mistakenly classiﬁed
as having IDA who in fact has TT, causes less damage than
the lack of this supplement to a patient with IDA who was
mistakenly classiﬁed as a TT carrier. Iron and erythropoietin
are required for the formation of hemoglobin.5 Furthermore,
iron is a component required in critical cellular processes
such as the transport and utilization of oxygen, production of
adenosine triphosphate (ATP), DNA synthesis, metabolism of
catecholamines, mitochondrial electron transport and other
physiological processes.23–25 Thus, biological systems includ-
ing the immune and neurological systems, are all affected by
the lack of iron.23 For these reasons the lack of treatment for
IDA would be very harmful to the individual.
Despite the moderate sensitivity for detecting patients
with thalassemia, application of the MCI  is still advantageous
if there is suspicion of this disorder. In this case, the patient
who  presented a value of MCI  >23.85 should be referred for
conﬁrmation by conventional methods. Nevertheless, in prac-
tical terms this is an advantage, because for this group, an
investigation of iron levels can be considered a second option.
The MCI  represents a breakthrough in discriminating
between IDA and TT, with potential for wide application
considering its advantage of being dependent only on the
number of RBCs and the MCHC. It should be noted that these
two parameters are obtainable from most simple cell counters,
therefore sophisticated automatic counters are not required.
Hence, the MCI  can be applied in areas where advanced tech-
nologies are not available in clinical labs.
Despite the advantages and simplicity of the implementa-
tion of the MCI  in the laboratory practice, there is a limitation
of MCI  and other discriminating formulas since they are not
able to differentiate all cases of IDA from TT. In light of this,
two situations can occur that deserve special attention: (i) the
index indicated TT, but the patient had IDA and (ii) the appli-
cation of the index indicated IDA, but the patient was a TT
carrier. In the ﬁrst case, patient follow-up is necessary and
will indicate, over time, a signiﬁcant reduction in circulating
hemoglobin levels, prompting the physician to request inves-
tigative tests of iron metabolism. In the latter situation, patient
follow-up is also needed which will show the need for medi-
cal procedures. In this case, the prescription of iron would not
increase the hemoglobin level due to the genetic disorder. In
cases of concomitant diseases, monitoring can also clarify the
best medical approach. Therefore, MCI  is a useful tool in guid-
ing the physician regarding the initial conduct to be adopted;
however, it does not eliminate the need of a follow-up that
eventually may require conﬁrmatory tests.
Conclusion
The MCI  has an excellent performance and may be poten-
tially useful for screening patients with microcytic anemias.
The routine use of the MCI  provided great diagnostic accuracy,
and could contribute decisively to guide the choice of con-
ﬁrmatory laboratory tests leading to a correct diagnosis and
treatment. This would result in a signiﬁcant cost saving for the
health system, especially advantageous in underdeveloped
and developing countries with limited ﬁnancial resources.
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